Godavari Drugs Gains 1.92%: Valuation Shift and Q2 Results Shape Weekly Moves
2026-11-14 15:03:18Key Events This Week Nov 09: Stock opens at Rs.121.00, up 1.09% Nov 11: Q2 FY27 results reveal modest growth but margin pressures; stock dips 2.40% Nov 12: Continued margin concerns weigh; stock declines 0.55% Nov 13: Valuation upgrade sparks 3.87% rally; week closes at Rs.122.00 Week OpenRs.119.70 Week Close<div clas...
Read More
Godavari Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-11-13 08:01:05Godavari Drugs Ltd has seen a marked improvement in its valuation parameters, shifting from an attractive to a very attractive grade, signalling a potential inflection point for investors. Despite a modest day decline of 0.55%, the pharmaceutical company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case relative to its peers and historical averages.
Read More
Godavari Drugs Ltd is Rated Hold by MarketsMOJO
2026-11-01 10:10:46Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 November 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Godavari Drugs Ltd is Rated Hold by MarketsMOJO
2026-10-21 10:10:56Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read MoreGodavari Drugs Ltd Surges 19.97%: Key Drivers Behind the Rally
2026-10-10 15:03:54Key Events This Week 05 Oct: Valuation shifts signal renewed price attractiveness 08 Oct: Sharp 9.77% intraday surge on heavy volume 09 Oct: New 52-week high at Rs.136.95, closing at Rs.140.00 (+8.40%) 09 Oct: Week closes with a 19.97% gain vs Sensex -0.57% Week OpenRs.116.70 Week CloseRs.140.0...
Read More
Godavari Drugs Ltd is Rated Hold by MarketsMOJO
2026-10-10 10:10:49Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 October 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Broad-Based Technical Strength Lifts Godavari Drugs Ltd to 52-Week High of Rs 136.95
2026-10-09 10:43:45With a sustained rally that has propelled Godavari Drugs Ltd to a fresh 52-week high of Rs 136.95 on 9 Oct 2026, the stock’s momentum is underpinned by a confluence of bullish technical indicators and consistent price strength over recent sessions.
Read More
Godavari Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-10-05 08:02:27Godavari Drugs Ltd has witnessed a notable improvement in its valuation parameters, moving from a 'very attractive' to an 'attractive' grade, reflecting a positive shift in price attractiveness amid a challenging pharmaceutical sector backdrop. This upgrade, coupled with robust returns relative to the Sensex, positions the micro-cap pharmaceutical player as a stock worth closer investor attention.
Read More
Godavari Drugs Ltd Upgraded to Hold on Technical and Valuation Improvements
2026-09-29 08:13:06Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 28 Sep 2026, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The pharmaceutical micro-cap’s enhanced technical trend, attractive valuation, and market-beating returns underpin this revised stance, although fundamental challenges remain.
Read MoreDisclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
18-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sushma Kakani
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
17-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Priyanka Jaju
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
17-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Tanushree Kakani
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available